Alemtuzumab is commonly used in transplant conditioning to prevent graft vs host disease. It is very effective, but when given intravenously it often causes rigors, chills and fevers. Khilna Patel, Pharm D recently reported how Subcutaneous administration is much better tolerated with fewer side-effects, and is equally effective.

Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan–Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation, BBMT Volume 22, Issue 3, March 2016, Pages 456–461